Citigroup Lowers Qiagen (NYSE:QGEN) Price Target to $38.00

Key Points

• Citigroup cut its price target on Qiagen from $55 to $38 and kept a "neutral" rating, implying roughly a 13% upside; the analyst consensus remains a "Hold" with an average price target of $49.98.
• Qiagen modestly beat Q1 EPS and revenue but management lowered Q2 and FY2026 guidance due to weaker QuantiFERON (TB) demand and geopolitical headwinds, a development that has pressured the stock toward its 12‑month low.
• A law firm has opened a shareholder investigation into Qiagen’s executives, creating potential legal/PR overhang, while institutional investors hold about 70% of the stock (market cap ≈ $6.9B).

Qiagen (NYSE:QGEN - Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $55.00 to $38.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a "neutral" rating on the stock. Citigroup's price objective would indicate a potential upside of 13.08% from the stock's previous close.

QGEN has been the topic of several other research reports. JPMorgan Chase & Co. raised their price target on shares of Qiagen from $55.00 to $60.00 and gave the company an "overweight" rating in a research report on Friday, February 6th. Jefferies Financial Group reissued a "buy" rating and set a $59.00 price objective on shares of Qiagen in a report on Thursday, February 5th. Stifel Nicolaus set a $50.00 price objective on Qiagen and gave the stock a "hold" rating in a research note on Friday, February 6th. Weiss Ratings restated a "hold (c)" rating on shares of Qiagen in a report on Friday, March 27th. Finally, Zacks Research downgraded Qiagen from a "hold" rating to a "strong sell" rating in a report on Monday, March 9th. Five analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $49.98.

Qiagen Trading Down 1.2%

QGEN stock traded down $0.41 during mid-day trading on Wednesday, reaching $33.61. The company's stock had a trading volume of 4,091,319 shares, compared to its average volume of 2,305,831. Qiagen has a 12 month low of $33.17 and a 12 month high of $57.81. The company has a current ratio of 3.90, a quick ratio of 3.31 and a debt-to-equity ratio of 0.44. The business's 50 day moving average price is $42.37 and its 200 day moving average price is $46.95. The company has a market cap of $6.93 billion, a price-to-earnings ratio of 16.67, a price-to-earnings-growth ratio of 1.97 and a beta of 0.79.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.01. The firm had revenue of $540.42 million for the quarter, compared to analyst estimates of $528.53 million. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The business's quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.61 earnings per share. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, equities research analysts predict that Qiagen will post 2.5 EPS for the current year.

Institutional Trading of Qiagen

Institutional investors have recently modified their holdings of the business. United Services Automobile Association purchased a new position in Qiagen in the 1st quarter valued at approximately $239,000. Prudential Financial Inc. boosted its holdings in shares of Qiagen by 74.9% in the second quarter. Prudential Financial Inc. now owns 8,873 shares of the company's stock worth $426,000 after acquiring an additional 3,799 shares during the period. Invesco Ltd. grew its position in shares of Qiagen by 123.7% in the second quarter. Invesco Ltd. now owns 1,006,025 shares of the company's stock valued at $48,350,000 after purchasing an additional 556,387 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Qiagen by 226.4% in the second quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company's stock valued at $125,000 after purchasing an additional 1,802 shares in the last quarter. Finally, First Trust Advisors LP bought a new stake in shares of Qiagen during the 2nd quarter valued at $3,639,000. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

More Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Q1 beat and profitability — Qiagen reported adjusted Q1 EPS in line with its outlook and slightly beat consensus on reported EPS, supporting margins and cash generation. Qiagen NV (QGEN) Q1 2026 Earnings Call Highlights: Navigating Mixed Sales with Strong Profitability
• Positive Sentiment: Adjusted EPS achieved and mixed but diversified portfolio — Preliminary Q1 results showed adjusted EPS achievement and growth in several non-QuantiFERON product lines, which tempers the revenue weakness. QIAGEN reports preliminary Q1 2026 results
• Neutral Sentiment: Earnings call details available — The full Q1 earnings call transcript provides management commentary on sales mix, TB test trends and cost control that investors can use for deeper color. Qiagen N.V. (QGEN) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Presentation slides published — The Q1 presentation lays out segment trends and the assumptions behind guidance revisions; useful for modeling near-term revenue and margin drivers. Qiagen N.V. 2026 Q1 - Results - Earnings Call Presentation
• Negative Sentiment: Guidance cut — Management lowered Q2 and FY2026 revenue and EPS targets below consensus, citing weaker demand; this is the primary driver of negative near-term revaluation. QGEN stock slumps after-hours on guidance cut tied to weak TB test demand
• Negative Sentiment: Weak QuantiFERON (TB) demand — Management specifically tied the guidance reduction to softer TB test sales, a concentrated headwind given QuantiFERON's importance to revenue. QGEN stock slumps after-hours on guidance cut tied to weak TB test demand
• Negative Sentiment: Geopolitical impact on sales — Qiagen cited Middle East tensions as a factor weighing on Q1 sales, contributing to the reported revenue softness and driving headlines about a multi-year low. Qiagen NV (QGEN) Falls to 7-Year Low as MidEast Tensions Drag Q1
• Negative Sentiment: Shareholder litigation risk — A law firm has opened an investigation into potential claims against Qiagen’s executives, which could create legal/PR overhang. Qiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel

About Qiagen

Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.